Glycogen synthase kinase-3 (GSK-3) and B-catenin: potential novel therapeutic targets for COPD
PhD ceremony: Mr. H.A. Baarsma, 16.15 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Glycogen synthase kinase-3 (GSK-3) and B-catenin: potential novel therapeutic targets for COPD
Promotor(s): prof. H. Meurs, prof. H.A.M. Kerstjens
Faculty: Mathematics and Natural Sciences
Hoeke Baarsma has demonstrated that both β-catenin and GSK-3 are important in specific cellular processes that contribute to the pathogenesis of COPD. Furthermore, he proposes that therapeutic intervention by GSK-3 inhibition may provide a novel therapeutic treatment for COPD.
Chronic obstructive pulmonary disease (COPD) is primarily caused by tobacco smoking and is characterized by a progressive decline of lung function. The persistent airflow limitation is the resultant of chronic inflammation and of structural alterations in the lungs, including airway remodeling and emphysema. Baarsma explored the functional roles of β-catenin and glycogen synthase kinase-3 (GSK-3), both critical effectors in the WNT-signaling pathway, in the pathological processes that underpin COPD.
Aberrant extracellular matrix (ECM) turnover is a pathological feature of COPD and contributes to the structural alterations in the lung. Baarsma demonstrated that activation of β-catenin contributes to ECM production by airway smooth muscle cells and pulmonary fibroblasts induced by the growth factor TGF-ß. Interestingly, this activation of the WNT pathway appeared enhanced in pulmonary fibroblasts of COPD patients. Moreover, the differentiation process of fibroblasts into more active myofibroblasts induced by TGF-β appeared dependent on both β-catenin and GSK-3. Further, the inflammatory response induced by exposure of airway smooth muscle cells to cigarette smoke appeared to be GSK-3 dependent.
Inhibition of GSK-3 protected against the ECM production and myofibroblast differentiation in lung fibroblasts. Moreover, in a guinea pig model of COPD GSK-3 inhibitors protected against airway fibrosis as well as extrapulmonary pathological features, such as right ventricle hypertrophy and skeletal muscle atrophy, which are similarly involved in COPD.
Last modified: | 13 March 2020 12.58 a.m. |
More news
-
24 May 2024
Lustrum 410 in pictures
Lustrum 410 in pictures: We are already over half way through our lustrum! Enjoy a few photos of the lustrum so far.
-
22 May 2024
Raffaella Carloni and Jonas Göbel winners Ben Feringa Impact Award 2024
Raffaella Carloni and Jonas Göbel received the Ben Feringa Impact Awards 2024 for the categories of researchers and students on Tuesday 21 May.
-
22 May 2024
2.9 million for sustainable management salt marshes Wadden Sea
Prof. Chris Smit (GELIFES) and Prof. Kai Jensen (University of Hamburg) will receive an NWA grant of 2.9 million euros for research that will contribute to sustainable managemnt of the salt marshes of the Wadden Sea.